Trastuzumab Emtansine for Injection

DRUG3 trials

Sponsors

Shanghai Miracogen Inc., Tianjin Medical University Cancer Institute and Hospital, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Conditions

Advanced Breast CancerHER2+ Advanced Breast Cancer Patients Progressing on TKI TherapyMetastatic Breast Cancer

Phase 2

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Shanghai Miracogen Inc.Advanced Breast Cancer, Metastatic Breast Cancer

Start: 2021-06-30End: 2023-10-31Target: 350Updated: 2023-03-17

Phase 3

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

RecruitingNCT07008976

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Metastatic Breast Cancer

Start: 2025-07-07End: 2028-12-31Target: 246Updated: 2025-08-14

Unknown Phase

Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy

Tianjin Medical University Cancer Institute and HospitalHER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy

Start: 2022-09-30End: 2025-08-23Target: 50Updated: 2022-10-03

Related Papers

Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial.

Journal of Clinical Oncology2024-06-011 citations